Alaunos Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 1
- Market Cap
- $4.4M
- Website
- http://www.alaunos.com
- Introduction
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The compa...
Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors
- First Posted Date
- 2008-01-11
- Last Posted Date
- 2012-07-19
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 10
- Registration Number
- NCT00591383
Study of ZIO-201 in Advanced Sarcoma
- First Posted Date
- 2007-02-26
- Last Posted Date
- 2014-01-31
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 53
- Registration Number
- NCT00439686
A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2013-11-14
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 17
- Registration Number
- NCT00423644
A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2013-11-14
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 15
- Registration Number
- NCT00423306
Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-01-11
- Last Posted Date
- 2012-07-19
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 50
- Registration Number
- NCT00421213
A Protocol for the Safety and Tolerance of Intravenous Isophosphoramide Mustard (IPM) in Patients With Advanced Cancer
- First Posted Date
- 2007-01-11
- Last Posted Date
- 2009-09-17
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT00421135
Study of ZIO-101 in Multiple Myeloma
- First Posted Date
- 2006-03-15
- Last Posted Date
- 2012-07-19
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 35
- Registration Number
- NCT00303199
© Copyright 2024. All Rights Reserved by MedPath